HSBC and 4 other SEBI-registered analysts issued 11 equity long term recommendations today, targeting multi-month to multi-year investment horizons. The batch carries a bullish bias — 11 buys against 0 sells — covering 7 stocks.

The 5 most-covered names of the session:

ZYDUSLIFE attracted 4 buys from HSBC (SEBI Reg. INH000001287) at ₹1,127, ₹1,141, ₹1,147 and ₹1,162, each targeting ₹1,100.

IDEA attracted 2 buys from CLSA (SEBI Reg. INH000001113) at ₹13.03 and ₹12, each targeting ₹13.

CGPOWER was flagged for a buy by Integratedresearchchannel (SEBI Reg. INH200006530) at ₹882.45, targeting ₹912 — a potential upside of +3.3%, with a stoploss at ₹859. The risk-to-reward ratio stands at 1:1.3.

HARSHA was flagged for a buy by Sislofficial (SEBI Reg. INH100005011) at ₹465, targeting ₹577 — a potential upside of +24.1%.

MOREPENLAB was flagged for a buy by Motilaloswalofficial (SEBI Reg. INH000000412) at ₹128.94, targeting ₹142 — a potential upside of +10.1%, with a stoploss at ₹122. The risk-to-reward ratio stands at 1:1.9.

The remaining 2 stocks covered by SEBI-registered analysts, with the price at which each call was issued:

Buy calls — SBC (₹58.74 → ₹1,100) via HSBC; SHILPAMED (₹1,074.9 → ₹1,182) via Motilaloswalofficial.

This roundup reproduces calls from 5 SEBI-registered Research Analysts: HSBC (SEBI Reg. INH000001287); CLSA (SEBI Reg. INH000001113); Motilaloswalofficial (SEBI Reg. INH000000412); Integratedresearchchannel (SEBI Reg. INH200006530); Sislofficial (SEBI Reg. INH100005011).

Long-term picks are best accumulated on dips. Investors should review fundamentals periodically and maintain position sizing discipline.

All recommendations reproduced here originate exclusively from SEBI-registered Research Analysts and are published for informational purposes only. These are not buy or sell recommendations from this publication. Registration with SEBI does not guarantee returns. Investing in securities markets is subject to market risks — read all related documents carefully before investing.